

Atroposelective Synthesis of Axially Chiral 4-Aryl α -Carbolines via *N*-Heterocyclic Carbene Catalysis

Rui Ma,[§] Xiaoxue Wang,[§] Qiaoyu Zhang, Lei Chen, Jian Gao, Jie Feng, Donghui Wei,^{*} and Ding Du^{*}



Cite This: *Org. Lett.* 2021, 23, 4267–4272



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: The first catalytic asymmetric construction of axially chiral 4-aryl α -carboline skeletons has been accomplished through an *N*-heterocyclic carbene (NHC)-catalyzed atroposelective formal [3 + 3] annulation of 4-nitrophenyl 3-arylpropiolates with 2-sulfonamidoindolines. The synthetic utility of the title compounds has been demonstrated by the diverse late-stage structural modifications. Density functional theory calculations were also conducted to illuminate the key factors for controlling the origin of the enantioselectivity. This strategy not only provides an efficient pathway to access axially chiral α -carboline atropisomers but also offers a novel catalytic enantioselective mode for the construction of axially chiral heterobiaryls by using NHC-bound alkynyl acylazoliums.



Axially chiral skeletons have been recognized as privileged structures because they not only are frequently found in numerous natural products and bioactive compounds¹ but also constitute the core structures of many chiral catalysts.² Therefore, the catalytic enantioselective synthesis of axially chiral molecules has attracted increasing interest among the scientific community.³ Considerable efforts have been devoted to exploring efficient and enantioselective methods to access phenyl- and naphthyl-based biaryl atropisomers.⁴ In contrast, the enantioselective construction of atropisomeric heterobiaryl skeletons is more challenging (Scheme 1a). In recent years, although significant progress has been made in the synthesis of a few atropisomeric heterobiaryls,⁵ the development of more catalytic asymmetric approaches to access novel axially chiral heterobiaryls with structural diversity is still in high demand.

α -Carbolines (pyridoindoles) are privileged structural motifs embedded in a diverse array of natural alkaloids and bioactive compounds with wide-ranging pharmacological properties such as antitumor, anti-inflammatory, antibacterial, antimalarial, and central-nervous system-stimulating activities (Scheme 1b).⁶ Compared with β -carbolines that have been intensively investigated, the synthetic approaches to α -carbolines are considerably less developed.⁷ In particular, to the best of our knowledge, there is no example realizing the atroposelective synthesis of axially chiral α -carbolines to date. Therefore, the design and exploration of more general and efficient methods to synthesize functionalized α -carbolines, in particular, enantio-enriched axially chiral α -carbolines, are of great importance.

Over the past decade, *N*-heterocyclic carbene (NHC) catalysis has emerged as a powerful tool to realize numerous nontraditional chemical transformations.⁸ The unique reactivity of NHCs has enabled the combination with different carbonyl compounds to access various centrally chiral

molecules; however, the application of NHC catalysis in the synthesis of axially chiral molecules has been far less explored.⁹ As a continuation of our research on the chemistry of NHC-bound alkynyl acylazolium,¹⁰ we conceive that a new ring could be efficiently constructed through the [3 + *m*] annulation of a binucleophile with the β -activated alkynyl acylazolium, and the axially chirality could be concomitantly created between the newly formed ring and the 2,6-disubstituted aryl of the alkynyl acylazolium (Scheme 1c). To fulfill this target, a series of new 4-nitrophenyl 3-naphthylpropiolates **1** were well designed and synthesized as the alkynyl acylazolium precursors. After careful screening and selection of the substrates and reaction conditions, we demonstrate herein an atroposelective synthesis of novel 4-naphthyl α -carbolines **3** through an NHC-catalyzed formal [3 + 3] annulation of 4-nitrophenyl 3-naphthylpropiolates **1** with 2-sulfonamidoindolines **2** that serve as a type of suitable C–N 1,3-binucleophiles for the construction of the α -carboline skeleton. The unique structure of 3-(2-substituted naphth-1-yl)propiolates **2** was found to be one of the key factors for the success of this protocol.

We commenced our study by the reaction of ester **1a** with *N*-Me 2-sulfonamidoindoline **2a** using Cs₂CO₃ as the base in 1,2-dichloroethane (DCE) under the catalysis of NHC precursor **A** (Table 1, entry 1). Fortunately, a mixture of the

Received: April 10, 2021


Published: May 11, 2021



(80:20). When substrates bearing electron-withdrawing or electron-donating groups at the four-, six-, or seven-positions on the naphthalene rings were examined, moderate to high yields and high er values were regularly obtained (**3e–w**). Notably, this protocol could well accommodate a wide range of substituents on the naphthalene rings, including substituted phenyls, naphthyls, 2-thienyl, halogens, alkyls, and a cyano group. However, when a substituted phenyl ring replaced the naphthalene ring in propiolates, significantly decreased er values were observed (**3x** and **3y**). The absolute configuration structure of products **3** was determined by the X-ray crystallography of the atropisomer of **3s** (**3s'**) and was further established to be (R) by a comparison between the CD (circular dichroism) of **3c'** and its ECD (electrostatic circular dichroism).¹¹ In addition, the stability of product **3c** was investigated. (See the SI.) No racemization was observed after stirring **3c** at 150 °C for 24 h, indicating the high stability of this kind of axially chiral 4-aryl α -carboline.

Subsequently, the investigation of the scope of 2-sulfonamidoindolines **2** was conducted (Scheme 3). It was

Scheme 3. Substrate Scope with Respect to the 2-Sulfonamidoindolines 2




found that N-protecting groups of substrates **2** had great influence on the reaction yields and enantioselectivity. On one hand, the replacement of *N*-Me with *N*-Et or *N*-Bn led to slightly decreased er values (**3aa** and **3ac**), and the *N*-Ph substrate almost afforded the racemic product **3ad**. On the other hand, the *N*-allyl substrate resulted in a slightly increased er value but with a significantly decreased yield (**3ab**). Then, 2-sulfonamidoindolines **2** with different substituents on the benzene ring were tested. As a result, products **3ae–ah** and **3aj** with substituents at the six- or seven-positions were obtained in moderate yields with maintained enantioselectivities. However, five- or eight-substituted products (**3ai** and **3ak**) were obtained with decreased enantioselectivities.


To further explore the synthetic utility of this methodology, a scale-up synthesis of **3c** and its atropisomer **3c'** on a 1 mmol scale was then carried out (Scheme 4a). Product **3c** was obtained in an almost maintained yield with almost maintained enantioselectivity under standard conditions. The reaction of **1c** with **2a** in the presence of the NHC precursor *ent*-**E** could

Scheme 4. Synthetic Applications


a) A scale-up synthesis of **3c and its atropisomer **3c'** (1 mmol scale)**




b) Late-stage modification of **3n**



c) Late-stage modification of **3c**



d) Synthesis of axially chiral phosphine catalyst **5' and its application**




also give **3c'** in a similar yield with similar enantioselectivity. It is noteworthy that the er values of the filtrates of **3c** and **3c'** could be enhanced to 97.4:2.6 and <1:99, respectively after one recrystallization.

The late-stage modification of the products was then conducted to demonstrate the utility of the developed protocol. Three classical coupling reactions of **3n** with $PhB(OH)_2$, piperidine, and 2-(tributylstannyl)pyridine afforded the corresponding products **3f**, **4a**, and **4b**, respectively, in moderate yields with maintained er values (Scheme 4b). Removal of the tosyl group of **3c** afforded product **4c** in an excellent yield with maintained enantioselectivity. **4c** was subsequently transformed to an *O*-triflate-protected intermediate that could couple with the two-position substituted pyridine reagent to get the 2-(pyridin-2-yl) α -carboline **4d** with almost maintained enantioselectivity (Scheme 4c). Moreover, the axially chiral 4-naphthyl- α -carboline **3c'** obtained after recrystallization with a higher optical purity was used for the synthesis of the axially chiral phosphine **5'**, and the enantioselectivity was retained even after five steps (Scheme 4d). A preliminary application of phosphine **5'** as an

organocatalyst in the dearomatization of 3-nitroindole **6** with allenolate **7** indicated that **5'** could promote the reaction, although the enantioselectivity of product **8** still needed to be improved. Thus the synthesized axially chiral 4-naphthyl- α -carboline should have potential in the exploration of a new class of chiral organocatalysts or ligands through further structural modification.

A plausible mechanism for the synthesis of product **3c** in the presence of the NHC precursor **E** is depicted in Scheme 5. The

Scheme 5. Proposed Reaction Mechanism



catalytic cycle starts with the addition of chiral NHC **I** to ester **1c** to give the key alkynyl acylazolium intermediate **II**. The subsequent conjugate addition of substrate **2a** to **II** under basic condition generates the allenolate intermediate **III**, which undergoes sequential proton transfer and tautomerization to form intermediate **IV**. The intramolecular nucleophilic attack of the nitrogen anion on the acylazolium of **IV** gives rise to the annulation intermediate **Int-1** with the loss of NHC **I** in the next catalytic cycle. Then, tosyl transfer from nitrogen to oxygen results in the formation of the more stable aromatized product **3c**.

To explore the origin of the stereoselectivity in this reaction, density functional theory (DFT) calculations were performed at the M06-2X/6-31G(d, p)//SMD_{acetone} level in Gaussian 09. As shown in Figure 1, two different reaction modes would lead to the corresponding diastereoisomer transition states for the formation of the allenolate intermediates, that is, **TS1R** and **TS1S**. The energy barrier of **TS1R** is 1.8 kcal/mol lower than that of **TS1S**, so the pathway corresponding to the R isomer should be dominant. The calculated result is consistent with




Figure 1. 2-D structures and relative free energies (kcal/mol) of **TS1R** and **TS1S**.

the experimental observation. Further analysis of the transition states **TS1R** and **TS1S** using noncovalent interaction (NCI) and atoms in molecules (AIM) methods indicated that the strength of the noncovalent interactions (that is, $LP \cdots \pi$ and the $C-H \cdots N$ hydrogen bond) is stronger in **TS1R** than in **TS1S**, which should be responsible for the energetic favorability of the R-configurational isomer pathway. (See Figure S2.)

In summary, we have documented an NHC-catalyzed atroposelective formal [3 + 3] annulation of 4-nitrophenyl 3-arylpropiolates **1** with 2-sulfonamidoindolines **2**, which features the efficient construction of the α -carboline skeleton with the concomitant creation of the axial chirality to afford a new class of 4-aryl α -carboline atropisomers **3** with high enantioselectivity. The synthetic utility of this protocol was also demonstrated by the versatile late-stage modification of the products. Moreover, DFT calculations were conducted to illuminate that the $LP \cdots \pi$ and $C-H \cdots N$ hydrogen-bond interactions should be the key factors for controlling the origin of the enantioselectivity. We believe that this method not only provides a solution to the challenges in the asymmetric synthesis of axially chiral aryl- α -carboline but also paves the way for the further investigation and application of alkynyl acylazoliums in the construction of other axially chiral molecules with structural diversity.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.orglett.1c01221>.

All experimental procedures, characterization, X-ray crystallographic data, CD, ECD, nuclear magnetic resonance (NMR), and HPLC spectra, and DFT calculations (PDF)

■ Accession Codes

CCDC 2059256 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

■ AUTHOR INFORMATION

Corresponding Authors

Donghui Wei – College of Chemistry, Zhengzhou University, Zhengzhou, Henan Province 450001, P. R. China; orcid.org/0000-0003-2820-282X; Email: donghuiwei@zzu.edu.cn

Ding Du – State Key Laboratory of Natural Medicines, Department of Organic Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China; orcid.org/0000-0002-4615-5433; Email: ddmn9999@cpu.edu.cn

Authors

Rui Ma – State Key Laboratory of Natural Medicines, Department of Organic Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China

Xiaoxue Wang – State Key Laboratory of Natural Medicines, Department of Organic Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China

Qiaoyu Zhang – College of Chemistry, Zhengzhou University, Zhengzhou, Henan Province 450001, P. R. China

Lei Chen – State Key Laboratory of Natural Medicines, Department of Organic Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China

Jian Gao – State Key Laboratory of Natural Medicines, Department of Organic Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China; orcid.org/0000-0003-0071-1972

Jie Feng – State Key Laboratory of Natural Medicines, Department of Organic Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China; orcid.org/0000-0002-8662-2198

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.orglett.1c01221>

Author Contributions

[§]R.M. and X.W. contributed equally.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank the National Natural Science Foundation of China (nos. 21572270 and 21702232) and the “Double First-Class” University Project (CPU2018GY02 and CPU2018GY35) for financial support.

REFERENCES

- (1) (a) Bringmann, G.; Gulder, T.; Gulder, T. A.; Breuning, M. *Chem. Rev.* **2011**, *111*, 563. (b) Kozłowski, M. C.; Morgan, B. J.; Linton, E. C. *Chem. Soc. Rev.* **2009**, *38*, 3193. (c) Bringmann, G.; Mutanyatta-Comar, J.; Knauer, M.; Abegaz, B. M. *Nat. Prod. Rep.* **2008**, *25*, 696. (d) Tatsuta, K.; Hosokawa, S. *Chem. Rec.* **2014**, *14*, 28. (e) Smyth, J. E.; Butler, N. M.; Keller, P. A. *Nat. Prod. Rep.* **2015**, *32*, 1562. (f) Laplante, S. R.; Fader, L. D.; Fandrick, K. R.; Fandrick, D. R.; Hücke, O.; Kemper, R.; Miller, S. P.; Edwards, P. J. *J. Med. Chem.* **2011**, *54*, 7005. (g) Clayden, J.; Moran, W. J.; Edwards, P. J.; LaPlante, S. R. *Angew. Chem., Int. Ed.* **2009**, *48*, 6398. (h) LaPlante, S. R.; Edwards, P. J.; Fader, L. D.; Jakalian, A.; Hücke, O. *ChemMedChem* **2011**, *6*, 505. (i) Toenjes, S. T.; Gustafson, J. L. *Future Med. Chem.* **2018**, *10*, 409.
- (2) Ma, Y. N.; Li, S. X.; Yang, S. D. *Acc. Chem. Res.* **2017**, *50*, 1480.
- (3) For selected reviews, see: (a) Kumarasamy, E.; Raghunathan, R.; Sibi, M. P.; Sivaguru, J. *Chem. Rev.* **2015**, *115*, 11239. (b) Zhang, S.; Liao, G.; Shi, B. *Youji Huaxue* **2019**, *39*, 1522. (c) Cheng, D. J.; Shao, Y. D. *Adv. Synth. Catal.* **2020**, *362*, 3081. (d) Corti, V.; Bertuzzi, G. *Synthesis* **2020**, *52*, 2450. (e) Bao, X.; Rodriguez, J.; Bonne, D. *Angew. Chem., Int. Ed.* **2020**, *59*, 12623. (f) Wencel-Delord, J.; Panossian, A.; Leroux, F. R.; Colobert, F. *Chem. Soc. Rev.* **2015**, *44*, 3418. (g) Bonne, D.; Rodriguez, J. *Chem. Commun.* **2017**, *53*, 12385. (h) Wang, Y. B.; Tan, B. *Acc. Chem. Res.* **2018**, *51*, 534. (i) Witzig, R. M.; Lotter, D.; Fäseke, V. C.; Sparr, C. *Chem. - Eur. J.* **2017**, *23*, 12960. (j) Li, T. Z.; Liu, S. J.; Tan, W.; Shi, F. *Chem. - Eur. J.* **2020**, *26*, 15779.
- (4) For selected examples, see: (a) Zhang, J.; Simon, M.; Golz, C.; Alcarazo, M. *Angew. Chem., Int. Ed.* **2020**, *59*, 5647. (b) Yang, H.; Sun, J.; Gu, W.; Tang, W. *J. Am. Chem. Soc.* **2020**, *142*, 8036. (c) Beleh, O. M.; Miller, E.; Toste, F. D.; Miller, S. J. *J. Am. Chem. Soc.* **2020**, *142*, 16461. (d) Zhu, K.; Xu, K.; Fang, Q.; Wang, Y.; Tang, B.; Zhang, F. *ACS Catal.* **2019**, *9*, 4951. (e) Witzig, R. M.; Fäseke, V. C.; Häussering, D.; Sparr, C. *Nat. Catal.* **2019**, *2*, 925. (f) Deng, R.; Xi, J.; Li, Q.; Gu, Z. *Chem.* **2019**, *5*, 1834. (g) Chen, X.; Gao, D.; Wang, D.; Xu, T.; Liu, W.; Tian, P.; Tong, X. *Angew. Chem., Int. Ed.* **2019**, *58*, 15334. (h) Yao, Q. J.; Zhang, S.; Zhan, B. B.; Shi, B. F. *Angew. Chem., Int. Ed.* **2017**, *56*, 6617. (i) Jolliffe, J. D.; Armstrong, R. J.; Smith, M. D. *Nat. Chem.* **2017**, *9*, 558. (j) Yu, C.; Huang, H.; Li, X.; Zhang, Y.; Wang, W. *J. Am. Chem. Soc.* **2016**, *138*, 6956. (k) Zhang, S.; Yao, Q.-J.; Liao, G.; Li, X.; Li, H.; Chen, H.-M.; Hong, X.; Shi, B.-F. *ACS Catal.* **2019**, *9*, 1956.
- (5) For selected examples, see: (a) Zhang, D.; Su, Z.; He, Q.; Wu, Z.; Zhou, Y.; Pan, C.; Liu, X.; Feng, X. *J. Am. Chem. Soc.* **2020**, *142*, 15975. (b) Xia, W.; An, Q. J.; Xiang, S. H.; Li, S.; Wang, Y. B.; Tan, B. *Angew. Chem., Int. Ed.* **2020**, *59*, 6775. (c) Chen, Y. H.; Li, H. H.; Zhang, X.; Xiang, S. H.; Li, S.; Tan, B. *Angew. Chem., Int. Ed.* **2020**, *59*, 11374. (d) Zhang, L.; Xiang, S. H.; Wang, J. J.; Xiao, J.; Wang, J. Q.; Tan, B. *Nat. Commun.* **2019**, *10*, 566. (e) Zhang, J.; Xu, Q.; Wu, J.; Fan, J.; Xie, M. *Org. Lett.* **2019**, *21*, 6361. (f) Ma, C.; Jiang, F.; Sheng, F. T.; Jiao, Y.; Mei, G. J.; Shi, F. *Angew. Chem., Int. Ed.* **2019**, *58*, 3014. (g) Jiang, F.; Chen, K. W.; Wu, P.; Zhang, Y. C.; Jiao, Y.; Shi, F. *Angew. Chem., Int. Ed.* **2019**, *58*, 15104. (h) He, X.-L.; Zhao, H.-R.; Song, X.; Jiang, B.; Du, W.; Chen, Y.-C. *ACS Catal.* **2019**, *9*, 4374. (i) Zhang, H. H.; Wang, C. S.; Li, C.; Mei, G. J.; Li, Y.; Shi, F. *Angew. Chem., Int. Ed.* **2017**, *56*, 116. (j) Wang, C. S.; Li, T. Z.; Liu, S. J.; Zhang, Y. C.; Deng, S.; Jiao, Y.; Shi, F. *Chin. J. Chem.* **2020**, *38*, 543. (k) Wang, Q.; Zhang, W. W.; Song, H.; Wang, J.; Zheng, C.; Gu, Q.; You, S. L. *J. Am. Chem. Soc.* **2020**, *142*, 15678. (l) Wang, F.; Qi, Z.; Zhao, Y.; Zhai, S.; Zheng, G.; Mi, R.; Huang, Z.; Zhu, X.; He, X.; Li, X. *Angew. Chem., Int. Ed.* **2020**, *59*, 13288. (m) Liu, Y.; Wu, X.; Li, S.; Xue, L.; Shan, C.; Zhao, Z.; Yan, H. *Angew. Chem., Int. Ed.* **2018**, *57*, 6491. (n) Wang, Y.-B.; Zheng, S.-C.; Hu, Y.-M.; Tan, B. *Nat. Commun.* **2017**, *8*, 15489. (o) Miyaji, R.; Asano, K.; Matsubara, S. *Chem. - Eur. J.* **2017**, *23*, 9996.
- (6) (a) Akkachairin, B.; Rodphon, W.; Reamtong, O.; Mungthin, M.; Tummatorn, J.; Thongsornkleeb, C.; Ruchirawat, S. *Bioorg. Chem.* **2020**, *98*, 103732. (b) Peczyńska-Czoch, W.; Pogran, F.; Kaczmarek, L.; Boratynski, J. *J. Med. Chem.* **1994**, *37*, 3503. (c) Jaromin, A.; Kozubek, A.; Suchoszek-Lukaniuk, K.; Malicka-Błaszkiewicz, M.; Peczyńska-Czoch, W.; Kaczmarek, L. *Drug Delivery* **2008**, *15*, 49. (d) Hu, Y.; Shi, H.; Zhou, M.; Ren, Q.; Zhu, W.; Zhang, W.; Zhang, Z.; Zhou, C.; Liu, Y.; Ding, X.; Shen, H. C.; Yan, S. F.; Dey, F.; Wu, W.; Zhai, G.; Zhou, Z.; Xu, Z.; Ji, Y.; Lv, H.; Jiang, T.; Wang, W.; Xu, Y.; Vercruysse, M.; Yao, X.; Mao, Y.; Yu, X.; Bradley, K.; Tan, X. *J. Med. Chem.* **2020**, *63*, 9623.
- (7) (a) Wadsworth, A. D.; Naysmith, B. J.; Brimble, M. A. *Eur. J. Med. Chem.* **2015**, *97*, 816. (b) Yang, T.-H.; Kuo, C.-W.; Kavala, V.; Konala, A.; Huang, C.-Y.; Yao, C.-F. *Chem. Commun.* **2017**, *53*, 1676. (c) Akkachairin, B.; Tummatorn, J.; Khamsuman, N.; Thongsornkleeb, C.; Ruchirawat, S. *J. Org. Chem.* **2018**, *83*, 11254. (d) Selvaraj, K.; Swamy, K. C. K. *J. Org. Chem.* **2018**, *83*, 15043. (e) Ali, S.; Li, Y.-X.; Anwar, S.; Yang, F.; Chen, Z.-S.; Liang, Y.-M. *J. Org. Chem.* **2012**, *77*, 424. (f) Ali, W.; Dahiya, A.; Pandey, R.; Alam, T.; Patel, B. K. *J. Org. Chem.* **2017**, *82*, 2089. (g) Wang, C.; Zhang, H.; Lang, B.; Ren, A.; Lu, P.; Wang, Y. *Org. Lett.* **2015**, *17*, 4412. (h) Wang, G.; You, X.; Gan, Y.; Liu, Y. *Org. Lett.* **2017**, *19*, 110. (i) Yu, S.; Li, Y.; Zhou, X.; Wang, H.; Kong, L.; Li, X. *Org. Lett.* **2016**, *18*, 2812. (j) Zhang, J.; Guo, M.; Chen, Y.; Zhang, S.; Wang, X.-N.; Chang, J. *Org. Lett.* **2019**, *21*, 1331. (k) Yang, M.; Meng, X.-H.; Wang, Z.; Gong, Y.; Zhao, Y.-L. *Org. Chem. Front.* **2020**, *7*, 3493.
- (8) For selected reviews, see: (a) Chen, X. Y.; Gao, Z. H.; Ye, S. *Acc. Chem. Res.* **2020**, *53*, 690. (b) Ohmiya, H. *ACS Catal.* **2020**, *10*, 6862. (c) Ishii, T.; Nagao, K.; Ohmiya, H. *Chem. Sci.* **2020**, *11*, 5630. (d) Liu, J.; Xing, X.-N.; Huang, J.-H.; Lu, L.-Q.; Xiao, W.-J. *Chem. Sci.* **2020**, *11*, 10605. (e) Chen, X.; Wang, H.; Jin, Z.; Chi, Y. R. *Chin. J. Chem.* **2020**, *38*, 1167. (f) Liu, Q.; Chen, X.-Y. *Org. Chem. Front.* **2020**, *7*, 2082. (g) Mondal, S.; Yetra, S. R.; Mukherjee, S.; Biju, A. T. *Acc. Chem. Res.* **2019**, *52*, 425. (h) Zhang, C.; Hooper, J. F.; Lupton, D. W. *ACS Catal.* **2017**, *7*, 2583. (i) Grossmann, A.; Enders, D. *Angew. Chem., Int. Ed.* **2012**, *51*, 314. (j) Wang, M. H.; Scheidt, K. A. *Angew. Chem., Int. Ed.* **2016**, *55*, 14912. (k) Flanagan, D. M.; Romanov-Mikhailidis, F.; White, N. A.; Rovis, T. *Chem. Rev.* **2015**, *115*, 9307. (l) Murauski, K. J. R.; Jaworski, A. A.; Scheidt, K. A. *Chem. Soc. Rev.* **2018**, *47*, 1773.
- (9) (a) Lu, S.; Poh, S. B.; Zhao, Y. *Angew. Chem., Int. Ed.* **2014**, *53*, 11041. (b) Xu, K.; Li, W.; Zhu, S.; Zhu, T. *Angew. Chem., Int. Ed.* **2019**, *58*, 17625. (c) Lu, S.; Ong, J.-Y.; Yang, H.; Poh, S. B.; Liew, X.; Seow, C. S. D.; Wong, M. W.; Zhao, Y. *J. Am. Chem. Soc.* **2019**, *141*,

17062. (d) Yang, G.; Guo, D.; Meng, D.; Wang, J. *Nat. Commun.* **2019**, *10*, 3062. (e) Zhao, C.; Guo, D.; Munkrup, K.; Huang, K. W.; Li, F.; Wang, J. *Nat. Commun.* **2018**, *9*, 611. (f) Bie, J.; Lang, M.; Wang, J. *Org. Lett.* **2018**, *20*, 5866. (g) Lu, S.; Poh, S. B.; Rong, Z. Q.; Zhao, Y. *Org. Lett.* **2019**, *21*, 6169. (h) Li, T.; Mou, C.; Qi, P.; Peng, X.; Jiang, S.; Hao, G.; Xue, W.; Yang, S.; Hao, L.; Chi, Y. R.; Jin, Z. *Angew. Chem., Int. Ed.* **2021**, *60*, 9362.

(10) (a) Cao, J.; Sun, K.; Dong, S.; Lu, T.; Dong, Y.; Du, D. *Org. Lett.* **2017**, *19*, 6724. (b) Mou, C.; Wu, J.; Huang, Z.; Sun, J.; Jin, Z.; Chi, Y. R. *Chem. Commun.* **2017**, *53*, 13359. (c) Sun, K.; Jin, S.; Zhu, J.; Zhang, X.; Gao, M.; Zhang, W.; Lu, T.; Du, D. *Adv. Synth. Catal.* **2018**, *360*, 4515. (d) Xie, Y.; Wang, J. *Chem. Commun.* **2018**, *54*, 4597. (e) Sun, K.; Jin, S.; Fang, S.; Ma, R.; Zhang, X.; Gao, M.; Zhang, W.; Lu, T.; Du, D. *Org. Chem. Front.* **2019**, *6*, 2291.

(11) For detailed experiments and discussion of the determination of the absolute configuration, please see the SI (Figures S1 and S2).

■ NOTE ADDED AFTER ASAP PUBLICATION

This paper originally published ASAP on May 11, 2021. As there were errors in some of the text and in Schemes 2–5, a corrected version was reposted on May 14, 2021.